Bimatoprost Ophthalmic Solution for Enhanced Eyelash Growth
Bimat
| Product dosage: 0.3mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $60.00 | $60.00 (0%) | 🛒 Add to cart |
| 2 | $50.00 | $120.00 $100.00 (17%) | 🛒 Add to cart |
| 3 | $43.33 | $180.00 $130.00 (28%) | 🛒 Add to cart |
| 4 | $42.50 | $240.00 $170.00 (29%) | 🛒 Add to cart |
| 5 | $40.00 | $300.00 $200.00 (33%) | 🛒 Add to cart |
| 6 | $38.33 | $360.00 $230.00 (36%) | 🛒 Add to cart |
| 7 | $37.14 | $420.00 $260.00 (38%) | 🛒 Add to cart |
| 8 | $36.25 | $480.00 $290.00 (40%) | 🛒 Add to cart |
| 9 | $34.44 | $540.00 $310.00 (43%) | 🛒 Add to cart |
| 10 | $33.00
Best per bottle | $600.00 $330.00 (45%) | 🛒 Add to cart |
Synonyms | |||
Bimatoprost ophthalmic solution 0.03% is a prostaglandin analog prescription medication specifically formulated to treat hypotrichosis of the eyelashes. Its primary mechanism of action targets the anagen (growth) phase of the eyelash hair cycle, promoting increased length, thickness, and darkness. Clinically proven and FDA-approved for this indication, it represents a significant advancement in dermatological and ophthalmic aesthetic treatments. This product requires careful medical supervision to ensure optimal outcomes and patient safety.
Features
- Active ingredient: Bimatoprost 0.03%
- Pharmaceutical class: Prostaglandin analog
- Presentation: Sterile, isotonic, buffered ophthalmic solution
- Dosage form: 3 mL translucent bottle with integrated sterile applicators
- Preservative: Benzalkonium chloride 0.05 mg/mL
- pH: Approximately 7.0-7.8
- Osmolarity: Approximately 260-330 mOsmol/kg
Benefits
- Promotes a statistically significant increase in overall eyelash prominence, including length, fullness, and darkness.
- Achieves measurable results, with studies showing improvement typically seen after 1-2 months of once-nightly application.
- Offers a targeted, non-invasive pharmacological alternative to cosmetic procedures like eyelash extensions or tints.
- Provides a predictable and consistent treatment outcome when applied as directed under medical supervision.
- The treatment effect is gradual and appears natural, avoiding an abrupt change in appearance.
- Effects are reversible upon discontinuation of the medication, allowing for treatment flexibility.
Common use
Bimatoprost ophthalmic solution is indicated for the treatment of hypotrichosis (inadequate or not enough eyelashes). It is used to enhance eyelash growth by increasing their length, thickness, and darkness. It is applied topically to the skin of the upper eyelid margin at the base of the eyelashes.
Dosage and direction
The recommended dosage is one application per day, administered in the evening. Prior to application, ensure your face is clean, makeup is removed, and contact lenses are taken out (may be reinserted after 15 minutes).
- Remove one sterile, single-use applicator from its tray.
- Holding the applicator horizontally, place one drop of solution onto the applicator’s area nearest the tip.
- Immediately draw the applicator carefully across the skin of the upper eyelid margin at the base of the eyelashes. Apply from the inner (near the nose) to the outer part of the lid.
- Do not apply to the lower eyelid. Blot any excess solution that runs or transfers outside the upper eyelid margin.
- Dispose of the applicator after a single use. Do not reuse an applicator, as this can lead to contamination and potential serious eye injury.
- Repeat the process for the opposite eyelid using a new, sterile applicator. Do not allow the tip of the bottle to contact surrounding structures, fingers, or any other surface, as this can contaminate the solution.
Precautions
- This product is for external use only. It is not for use in the eye or on the lower lid.
- If any solution enters the eye, do not rinse the eye, as this is not expected to cause harm.
- Use caution when driving or operating machinery until the effects of any accidental exposure are known.
- Contains benzalkonium chloride, which may be absorbed by soft contact lenses. Remove contact lenses prior to application and wait at least 15 minutes before reinsertion.
- Potential for hair growth to occur in skin areas that the solution frequently touches. Any excess solution outside the upper eyelid margin should be blotted away to minimize this risk.
- May cause permanent darkening of the eyelid skin and iris (the colored part of the eye), which is likely to be irreversible. Iris pigmentation changes may be gradual and may not be noticeable for months to years.
- The solution may be harmful if ingested. Keep out of reach of children.
Contraindications
This medication is contraindicated in patients with a known hypersensitivity to bimatoprost, benzalkonium chloride, or any other component of the formulation.
Possible side effect
The most common side effects (occurring in approximately 3-4% of patients) are eye pruritus (itching), conjunctival hyperemia (eye redness), skin hyperpigmentation (darkening of the skin on the eyelid), ocular irritation, dry eye symptoms, and erythema of the eyelid. Less common side effects include:
- Blepharitis (inflammation of the eyelid)
- Cataract
- Photophobia (light sensitivity)
- Periorbital edema (swelling around the eyes)
- Superficial punctate keratitis (corneal inflammation)
- Eye discharge
- Tearing
- Visual disturbance
- Asthenopia (eye strain)
- Allergic reactions (localized or conjunctivitis)
- Headache
- Increased brown iris pigmentation (which is likely permanent)
Drug interaction
Formal topical drug interaction studies have not been conducted with bimatoprost ophthalmic solution for eyelash growth. There is a potential for an additive effect when used concomitantly with other prostaglandin analogs administered intraocularly for the treatment of elevated intraocular pressure (e.g., glaucoma). Inform your healthcare provider of all medications you are using, including prescription, over-the-counter, and herbal products.
Missed dose
If a dose is missed, skip that dose and resume the usual schedule the following evening. Do not apply a double dose to make up for the missed application.
Overdose
No case of overdose with topical ocular administration has been reported. If the bottle contents are ingested, appropriate supportive measures should be taken based on the symptoms presented. Given the small total volume of the bottle, significant systemic toxicity is unlikely, but medical advice should be sought.
Storage
Store the product at 2°C to 25°C (36°F to 77°F). Once opened, the bottle can be used until the expiration date printed on the bottle. Do not freeze. Keep the bottle tightly closed when not in use to prevent contamination.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
- “As a board-certified dermatologist, I have prescribed bimatoprost for appropriate patients with hypotrichosis for over five years. The results are consistently measurable and significant. Patient satisfaction is high, provided they are properly counseled on the application technique and potential for iris/skin darkening. It remains the gold-standard pharmacological treatment in my practice.” – Dr. E. Vance, MD, Dermatology
- “From a clinical trial perspective, the data supporting bimatoprost’s efficacy is robust. The double-blind, placebo-controlled studies clearly demonstrated a positive impact on all primary endpoints: eyelash length, thickness, and darkness. It is a well-characterized product with a predictable safety profile when used as indicated.” – Clinical Research Associate
- “I advise my patients that this is a treatment, not a cosmetic. It requires patience, as results take time. The key to success and minimizing side effects is meticulous application. Patients who follow the directions precisely achieve excellent results with minimal adverse events.” – Ophthalmology Nurse Practitioner
- “After reviewing the pharmacovigilance data, the side effect profile is well-established and generally mild and local. The risk of permanent iris darkening, while a serious consideration, appears to be low with topical application to the lid margin compared to direct instillation into the eye for glaucoma. Patient selection and education are paramount.” – Pharmacovigilance Specialist